NUCLEAR ONCOLOGY
Nuclear Oncology for Targeted Cancer Treatment
Nuclear Oncology combines molecular imaging with radiotheranostics (sometimes referred to as Peptide Receptor Radionuclide Therapy (PRRT)) which are injectable radiopharmaceuticals with antitumor effects. Spect CT imaging is utilized in staging and follow-up to visualize the effectiveness of the treatment and progress in reducing or eliminating cancerous tumor cells.
LUTATHERA
LUTATHERA is a prescription treatment for adults with specific types of cancer. The therapy is delivered via intravenous infusion and is designed to attach to targeted cancer cells. Once delivered, LUTATHERA introduces radiation to the tumor damaging the targeted cells. Until recently, local patients were required to travel to a large medical center outside the region to receive this therapy. LUTATHERA is now available to patients in the Inland Northwest through the Nuclear Medicine and Interventional Radiology Departments at Inland Imaging.
Patient Testimonials
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.”
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.”
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.”
Frequently Asked Questions
Nuclear Oncology is an advanced cancer treatment approach that combines molecular imaging with radiotheranostics, injectable radiopharmaceuticals designed to target and damage cancer cells. This therapy, also known as Peptide Receptor Radionuclide Therapy (PRRT), delivers targeted radiation directly to tumors while minimizing impact on healthy tissue.
Nuclear Oncology is used to treat specific types of cancer, particularly neuroendocrine tumors. Your oncologist will determine if this treatment is appropriate based on your specific diagnosis and medical history.
LUTATHERA is an FDA-approved radiotheranostic treatment delivered through intravenous infusion. It’s designed to attach to targeted cancer cells and introduce radiation directly to the tumor, damaging cancerous cells while sparing healthy tissue. Previously, patients had to travel outside the region for this treatment, but it’s now available locally at Inland Imaging.
A LUTATHERA infusion typically takes several hours to complete. Your healthcare team will provide specific details about your treatment schedule, which usually involves multiple infusion sessions spaced weeks apart.
Yes, Nuclear Oncology treatments like LUTATHERA require a referral from your oncologist or healthcare provider. Your doctor will evaluate whether you’re a candidate for this therapy based on your specific condition.
During treatment, you’ll receive an intravenous infusion while being monitored by our specialized team. The radiotheranostic medication will circulate through your body and target cancer cells. Your care team will provide detailed preparation instructions and what to expect during and after each session.